학술논문

Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease
Document Type
Artikel
Source
The oncologist. 25(4):E709-E715
Subject
Medicin och hälsovetenskap
Language
English
English
ISSN
1549-490X